DS-2969b is an orally active GyrB inhibitor with antibacterial activity. DS-2969b is is active against Clostridium difficile infection (MIC 90 : 0.06 μg/mL), which is 2-, 16-, and 32-fold lower than those of Fidaxomicin ( HY-17580 ), Metronidazole ( HY-B0318 ), and Vancomycin ( HY-B0671 ), respectively. DS-2969b inhibits the supercoiling activity of C. difficile DNA gyrase. DS-2969b also exhibits activity against other Gram-positive anaerobes, including strict and facultative anaerobes. DS-2969b is safe and well tolerated in preclinical toxicology studies.
Products | Products > Disease Areas > Infection | Products > Signaling Pathways > Anti-infection | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Infection | Products > Signaling Pathways > Bacterial | Products > Signaling Pathways > DNA/RNA Synthesis
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.